Healthcare / BiotechnologyNasdaqCM
$1.29
-0.02 (-1.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-12.8M · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$4M
P/E
0.7x
↓EV/EBITDA
N/A
•ROE
-23.7%
↓Gross Margin
96.5%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2008–2025 · 17 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-6579.2%
FCF / Net income
3.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $144000.0 · net income $-2.5M · FCF $-9.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||||
| Revenue | $144000.00 | $144000.00 | $109000.00 | $370000.00 | $1.5M | $0.00 | $2.2M | $3.1M | $4.6M | $3.2M | $806000.00 | $314000.00 | $0.00 | — | $0.00 | $969000.00 | — | — | — |
| Net Income | $-2.5M | $-2.5M | $-14.7M | $-17.3M | $-11.4M | $-16.8M | $-18.7M | $-26.6M | $-34.8M | $-38.4M | $-38.6M | $-30.1M | $-25.8M | — | $-43.6M | $-4.4M | $-1.3M | $-872000.00 | $-98000.00 |
| EBITDA | $-2.2M | $-2.2M | $-14.4M | $-17.4M | $-11.3M | $-16.8M | $-20.3M | $-26.3M | $-34.0M | $-37.4M | $-37.8M | $-29.8M | $-20.3M | — | $-9.1M | $-2.2M | — | — | — |
| EPS | -1.70 | -1.70 | -19.25 | -23.76 | -15.84 | — | — | — | — | — | — | — | — | — | -232.80 | -45.60 | — | — | — |
| Gross Margin | 96.5% | 96.5% | 100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -8761.1% | -8761.1% | -13840.4% | -4792.2% | -765.3% | — | -977.9% | -882.4% | -766.3% | -1218.0% | -4794.4% | -9648.7% | — | — | — | -237.9% | — | — | — |
| Net Margin | -1727.8% | -1727.8% | -13459.6% | -4664.6% | -763.2% | — | -852.0% | -861.7% | -756.1% | -1214.0% | -4786.0% | -9580.3% | — | — | — | -452.3% | — | — | — |
| Balance Sheet | |||||||||||||||||||
| Debt/Equity | 0.09 | 0.09 | 0.39 | 0.12 | 0.07 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 2.44 | 2.44 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||||
| Free Cash Flow | $-9.5M | $-9.5M | $-14.7M | $-12.8M | $-8.9M | $-13.7M | $-14.9M | $-20.5M | $-29.1M | — | — | — | $-15.8M | — | $-13.4M | $-2.0M | — | — | — |
| Returns | |||||||||||||||||||
| ROE | -23.7% | -23.7% | -407.4% | -112.6% | -37.9% | -42.9% | -70.3% | -73.4% | -78.1% | -61.7% | -62.0% | -61.8% | -53.5% | — | 821.3% | — | — | — | — |
| Valuation | |||||||||||||||||||
| P/E | 0.73 | 0.73 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.18 | 0.18 | 2.59 | 1.23 | 1.07 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||||
| Revenue Growth | 32.1% | 32.1% | -70.5% | -75.3% | — | -100.0% | -29.0% | -32.8% | 45.3% | 292.9% | 156.7% | — | — | — | -100.0% | — | — | — | — |
| EPS Growth | 91.2% | 91.2% | 19.0% | -50.0% | — | — | — | — | — | — | — | — | — | — | -410.5% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-19.25 → -1.70
Residual
-28.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.